Lv2
179 积分 2021-07-29 加入
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study
14小时前
已完结
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study
9天前
已完结
Chinese consensus on first-line precision therapy for advanced gastric cancer
24天前
已完结
Concordance of PD-L1 Expression in Metastatic Triple-negative Breast Cancer Between the 22C3 and E1L3N Antibodies Using Combined Positive Scoring
1个月前
已完结
Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
1个月前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2个月前
已完结
Bispecific T-cell engagers (BiTE): a review of tarlatamab in small cell lung cancer
2个月前
已完结
Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial
3个月前
已完结
Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial
3个月前
已完结
Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis
3个月前
已完结
皖公网安备34019202002308
